- Report
- June 2020
- 224 Pages
From €2700EUR$3,104USD£2,402GBP
€3000EUR$3,449USD£2,669GBP
From €3131EUR$3,600USD£2,786GBP
- Report
- December 2019
- 200 Pages
From €3479EUR$4,000USD£3,095GBP
From €4671EUR$5,370USD£4,155GBP
- Report
- July 2020
- 95 Pages
From €743EUR$854USD£661GBP
€825EUR$949USD£734GBP
- Report
- November 2019
- 300 Pages
- Report
- November 2019
- 299 Pages
- Report
- February 2019
- 117 Pages
From €2174EUR$2,500USD£1,935GBP
- Report
- May 2018
- 94 Pages
From €5175EUR$5,950USD£4,604GBP
From €3040EUR$3,495USD£2,704GBP
- Report
- February 2016
- 148 Pages
From €4566EUR$5,250USD£4,062GBP
- Report
- September 2020
- 2189 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2006 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2103 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2066 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2001 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2027 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2111 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2134 Pages
€3349EUR$3,850USD£2,979GBP
- Report
- September 2020
- 2011 Pages
€3349EUR$3,850USD£2,979GBP

Far less common than breast cancer, but with a higher mortality rate, sufferers of ovarian cancer are experiencing significant unmet needs. There are therefore considerable market opportunities for drug designers and manufacturers in this life-saving sector of the pharmaceutical industry. In this section a host of cutting edge reports provide valuable insight into key markets such as China and the US, the latest drug development activities and the market trends (including sales, pricing and forecasts) for specific drugs like Doxil, Caelyx, Yondelis and Paclitaxel. You can also purchase reports that feature the latest strategies of major and niche industry players such as Alza Corporation, Amgen, Bristol-Myers Squibb, Cell Therapeutics, Genentech, GlaxoSmithKline, Immunogen, Ivax, OSI Pharmaceuticals and Raven Biotechnologies.
Show Less Read more